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ABSTRACT 
ERBB receptor transmodulation by heterologous G-protein coupled receptors (GPCRs) 
generates functional diversity in signal transduction. Tachykinins are neuropeptides and 
proinflammatory cytokines that promote cell survival and cancer progression by activating 
several GPCRs. In this work, we found that the pain-associated tachykinin Substance P (SP) 
contributes to persistent transmodulation of the ERBB receptors EGFR and HER2 in breast 
cancer (BC), acting to enhance malignancy and therapeutic resistance. SP and its high-affinity 
receptor NK-1R were highly expressed in HER2+ primary breast tumors (relative to the 
luminal and triple negative subtypes), and were overall correlated with poor prognosis factors. 
In BC cell lines and primary cultures derived from BC samples, we found that SP could 
activate HER2. Conversely, RNAi-mediated attenuation of NK-1R, or its chemical inhibition, 
or suppression of overall GPCR-mediated signaling, all strongly decreased steady-state 
expression EGFR and HER2, establishing that their basal activity relied upon transdirectional 
activation by GPCR. Thus, SP exposure affected cellular responses to anti-ERBB therapies. 
Our work reveals an important oncogenic co-operation between NK-1R and HER2, thereby 
adding a novel link between inflammation and cancer progression that may be targetable by 
SP antagonists that have been clinically explored.  
 
INTRODUCCION 
Inflammation is a hallmark of cancer (1). Chronic inflammation is closely related to tumor 
development and progression; it supplies the tumor with a milieu of proinflammatory cytokines that 
can modulate the inflammation-related tumor cell signaling (2, 3). Some inflammatory conditions 
increase the risk of the onset of cancer by enhancing the proliferation and oncogenic potential of 
adjacent epithelia. In cancers that are already established, persistent inflammation enhances tumor 
growth and progression by activating several mechanisms that supports tumors, such as enhanced 
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angiogenesis and stromal cell recruitment. Inflammatory mediators can also cause genetic instability 
(4, 5) and favor the fixation of epigenetic alterations (6).  
Several proinflammatory cytokines, such as chemokines, induce signal transduction through 
different families of G-protein coupled receptors (GPCRs). Activation of secondary messengers, 
such as PKC and adenylate cyclase, results in the diversification G-protein signal transduction (7, 8). 
In some cancer cell types, the mitogenic stimulus activated by G-proteins is partly mediated by 
transmodulation of the EGFR (epidermal growth factor receptor) (9, 10). The members of the ERBB 
family, including EGFR, HER2, HER3 and HER4, are receptors with tyrosine kinase (RTK) activity, 
and signaling networks triggered by them play a pivotal role in tumor initiation and progression (11, 
12). In particular, HER2 is overexpressed in approximately 25% of breast cancer (BC) patients and is 
associated with worse prognosis and lower survival rates (13, 14). The precise pathways 
interconnected with RTK to fine tune cellular responses are still unknown, but emerging evidence 
indicates that transmodulation by heterologous GPCRs may play an important role in them (7, 8). It 
is particularly noteworthy that the crosstalk between GPCRs and RTKs allows for RTK activation 
even in the absence of ligands (7). Therefore, identifying of new modulators of RTKs activity could 
be highly useful in the search for new therapeutic targets. 
In this work, we have investigated the transmodulation of the ERBB system by the 
neuropeptide/proinflammatory mediator Substance P (SP); a pleiotropic molecule synthesized by the 
TAC1 gene. SP is related to processes of neurogenic inflammation, wound healing, hematopoiesis, 
microvasculature permeability, leukocyte trafficking, cell survival, and metastatic dissemination (15-
19). The three classical members of the mammalian tachykinin family are SP and neurokinin A 
(NKA), both enconded by the TAC1 gene, and neurokinin B (NKB) encoded by the TAC3 gene. 
There is a third mammalian tachykinin gene (TAC4) that codifies for hemokinins and endokinins (15, 
20, 21). These tachykinins exercise their biological functions through their preferential binding to the 
tachykinin receptors NK-1R (TACR1), NK-2R (TACR2) and NK-3R (TACR3), respectively, although 
each tachykinin can bind to the three tachykinin receptors with different affinity (22). NK-1R, the 
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high-affinity SP receptor, is a GPCR that is overexpressed in BC (19). In this work, we identify a 
new aberrant signaling network in BC based on the oncogenic co-operation between the 
tachykinergic system and HER2/EGFR signaling. The data presented here supports the idea that the 
SP produced within a proinflammatory setting can enhance tumor malignancy by activating HER2 
and EGFR. In addition, we demonstrated that the network could be exploited for the development of 
new therapeutic strategies based on the dual inhibition of activation and transactivation mechanisms. 
 
MATERIAL AND METHODS 
Cell lines. All human BC cell lines were purchased from American Type Culture Collection and 
were validated by single locus short tandem repeat (STR) typing (Bio-Synthesis, Inc.) prior to its use. 
Isolation of human primary breast cancer cells. Nineteen histologically confirmed BC tumors 
were collected at the Hospital Clinic in Barcelona under the approval of the institutional review 
board. Tumor tissue was processed to obtain single cells by digestion with a mixture of collagenase 
and hyaluronidase, as previously described (43), and the cells were frozen in FBS with 10% DMSO 
until further analysis.  
Time-course studies. In cell lines: To determine the effects of SP treatment on HER2, EGFR, 
p42/44 MAPK and Akt activation cells treated at the indicated times with SP 100 nM, washed, and 
rapidly frozen until protein extraction. In primary cultures: Tumor cells were thawed, filtered to 
ensure single-cell suspensions, and kept in Mammary Epithelial Basal Medium (MEBM®, Lonza, 
Cologne) supplemented with growth factors for 3 hours at 37ºC. Each single-cell suspension was 
split into 3 groups: control, SP 6 min and SP 10 min. They were serum starved for 2 hours, and then 
treated with PBS or SP 100 nM at 37°C. After treatment, the cells were washed, fixed in PFA 4%, 
and resuspended in PBS with glycerol 10%. A Cytospin slide centrifuge was used to concentrate and 
fix the samples on glass slides until further immunodetection of activated HER2. 
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In vivo experiments. Animal experiments were performed in accordance with the regulations of our 
institution’s ethics commission, following the guidelines established by the regional authorities of 
Catalonia, Spain. The specific procedures are outlined in the Supplementary Methods on line. 
Western blot. Briefly, cells or tumor pieces were lysed in ice-cold radioimmunoprecipitation assay 
buffer (RIPA). Protein quantification and detection was performed as described elsewhere applying 
the primary antibodies at the dilutions indicated in the Supplementary Methods on line. 
Immunofluorescence. Cell lines and cytopin slides containing the cells from the primary cultures 
were immunostained with a combination of different antibodies as explained in the Supplementary 
Methods online. The slides were counterstained with DAPI (Roche Diagnostic, Germany) for 15 
minutes and mounted with a coverslip using ProLong® Gold antifade reagent (Invitrogen, Molecular 
Probes, CA).  
Fluorescence microscopy and image acquisition. Images were acquired using a Leica TCS SP5 
laser scanning confocal microscope (Leica Microsystems Heidelberg GmbH, Manheim, Germany). 
In the images of the primary cultures, the mean fluorescence (pHER2 staining) (Integrated 
density/Area) of selected cells (those pan-CK positive) was quantified using a custom macro in the 
FIJI software (a distribution of ImageJ-Wayne Rasband, NIH, USA) as explained in detail in the 
Supplementary Methods online. 
Tumor subtype classification. Tumor subtype definitions in this study were as follows: luminal A 
(ER+ and/or PR+, HER2-), luminal B (ER+ and/or PR+, HER2+), HER2+ (ER-, PR-, HER2+), 
basal-like (ER-, PR-, HER2-, CK5/6+, and/or EGFR+), and unclassified (negative for all markers), 
as previously described (45).  
Immunohistochemistry procedure and evaluation. Immunohistochemistry for NK-1R, NK-2R, 
SP, COX2, or SMA was performed following standard protocols as indicated in the Supplementary 
Methods online. For the semi-quantitative analysis, an immunoreactive score (IRS) was derived by 
multiplying the percentage of positive cells (PP) by the staining intensity (SI). The SI was 
determined as: 0 for no staining; 1+ for weak staining; 2+ for moderate staining; 3+ for strong 
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staining and 4+ for very strong staining. We classified the IRS into 4 groups: 0 (negative staining), 1 
(staining score >0 and <100), 2 (staining score >100 and <200), 3 (staining score >200).  
Statistical analysis. Detailed statistic methods used to compare differences between groups can be 
found in the Supplementary Methods online.  
 
RESULTS 
NK-1R and SP are highly expressed in human primary tumors of the HER2+ subtype, and 
circulating SP levels are increased in BC patients 
The expression levels of NK-1R, NK-2R and SP were scored as both continuous and ordinal 
variables (for further details see the Methods section) (Supplementary Table S1 and S2), and both 
statistical analyses showed similar correlations with clinical characteristics. NK-1R, NK-2R, and SP 
were expressed by luminal cells from normal breast tissue (Supplementary Fig. S1), and 
overexpressed in tumors (Fig. 1A), in agreement with previous reports (19). In tumors, NK-1R, NK-
2R, and SP expression was detected in 94%, 86% and 52% of the 318 samples analyzed, respectively 
(Fig. 1A-C). With few exceptions, we did not find significant intratumor heterogeneity for the 
expression of these proteins; when present they were expressed in the majority of the cells within 
each tumor. Expression of either NK-1R or SP was positively associated with tumor histopathologic 
characteristics related to poor prognosis. For example, NK-1R expression levels were associated with 
estrogen receptor (ER) and progesterone receptor (PR) negativity, and p53 overexpression. SP 
expression was associated with a high histological grade, ER and PR negativity, and a high Ki67 
proliferation index. In contrast, NK-2R expression was associated with low histologic grade, ER and 
PR positivity, and no p53 overexpression (Supplementary Tables S1 and S2). Interestingly, we found 
that NK-1R and SP expression were significantly higher in tumors of the HER2+ subtype, when the 
expression levels were considered as either continuous or ordinal variables (Fig. 1D-I), and the same 
positive association was found in tumors with HER2 gene amplification (Supplementary Tables S1 
and S2). In contrast, NK-2R expression was lowest in this particular tumor subtype (Fig. 1E and 1H).  
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 We next determined the SP concentration in the serum of 139 BC patients and 92 healthy 
controls by ELISA. The levels of SP were significantly higher in BC patients than in healthy 
controls, although we did not observed any association with a particular tumor subtype or any other 
clinicopathologic characteristic (Fig. 1J and Supplementary Table S3).  
 
Human tachykinins modulate EGFR and HER2 receptor activation in BC cells 
Considering that the higher expression of NK-1R and SP in HER2+ tumors could be the 
consequence of functional co-operation between the two signaling systems, we next explored the 
effects of SP on a panel of BC cell lines with (MDA-MB-453, SK-BR-3, BT-474) and without 
(MDA-MB-231, MCF7) amplification or overexpression of the ERBB2 gene (23), and with 
overexpression of the EGFR gene (MDA-MB-468) (Fig. 2A). We detected expression of the three 
main tachykinin receptors, TACR1, TACR2 and TACR3, and expression of TAC1 (which codifies for 
SP) by qPCR in all the cell lines (Fig. 2B). We further confirmed the expression of NK-1R and SP 
by immunofluorescence in all the cell lines (Fig. 2C). Through time-course studies, we observed that 
SP quickly induced the phosphorylation of HER2 Tyr1248 (specific tyrosine residue that serves as 
docking site for the adaptor molecules that will activate the Ras-ERK pathways (24-26)) within the 
first 6 to 10 minutes after stimulation in all the cell lines (Fig. 2D; the densitometric quantification is 
shown in Supplementary Fig. S2A). The activation of HER2 within this time frame was consistently 
observed in all the replicates performed, although the exact time-point of maximum activation 
varied. The kinetics of HER2 receptor activation was dose-dependent, showing faster activation with 
increasing concentrations of SP (Supplementary Fig. S3). SP treatment also induced the 
phosphorylation of EGFR Tyr1068 (ligand-activated) (27) and EGFR Tyr845 (Src-activated) (28), as 
well as the p42/44 MAPK and Akt pathways (Fig. 2D and Supplementary Fig. S2A).  
By immunofluorescence we also observed an increase in the levels of phospho-HER2 Y1248 
in the cell membrane of MDA-MB-453 cells (HER2+) and an increase in the formation of endocytic 
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vesicles containing activated EGFR in the MDA-MB-468 cell line (EGFR+) (29) (Supplementary 
Fig. S2B) after SP treatment.  
The MAPK is a common downstream pathway triggered by both HER2 and NK-1R 
activation (7, 30, 31). Then, to confirm that the phosphorylation of HER2 caused by SP treatment 
was indeed activating HER2 receptor we determined the capability of SP to activate the MAPK 
pathway in the presence of HER2 inhibitors. Using the MDA-MB-453 cell line we observed that the 
inhibition of HER2 with either Lapatinib or AG825 decreased the capability of SP to activate the 
p42/44-MAPK (Supplementary Fig. S4A and B), suggesting that the activation of MAPK by SP 
partially depends on the transactivation of HER2. 
 
SP transactivates HER2 in human primary tumor cells 
Since HER2 is a target for therapy in BC patients, we next studied the clinical relevance of 
SP-mediated HER2 activation. We determined the activation of phospho-HER2 Y1248 after SP 
treatment for 6 and 10 minutes in 1896 single cells obtained from 19 BC primary cultures of 
different cancer subtypes that were classified by immunohistochemistry as having some degree of 
expression of HER2 (Supplementary Fig. S5 and Supplementary Table S4). We used multicolor 
immunofluorescence and confocal microscopy to analyze and quantify the levels of phospho-HER2 
Y1248 in pan-cytokeratin positive cells (to select only epithelial cells) (Fig. 3A). The basal levels of 
phospho-HER2 Y1248 were higher in the control samples derived from HER2+ and luminal B 
tumors than in the luminal A or triple negative tumors (Fig. 3B and C). Although overall we only 
observed a statistically significant increase in phosho-HER2 Y1248 by SP in cells derived from 
tumors of the HER2+ and triple negative subtypes (Fig. 3D), there was some inter-group variation in 
the tumors of the luminal A subtype. In fact, in 7 out of 10 luminal A tumors, SP activated HER2, in 
agreement with the results obtained with BC cell lines (Supplementary Fig. S6). We did not observed 
activation of HER2 in the cells derived from luminal B tumors at the time points tested. There could 
be several reasons for the lack of HER2 activation in this subgroup; for instance, due to low levels of 
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NK-1R expression in luminal B compared to HER2+ tumors (Fig. 1D); or because of a lack of 
additional signaling mediators involved in the transactivation process with differential intracellular 
signaling.  
 
SP/NK-1R autocrine/paracrine signaling in BC cells elicits a constitutive transactivation of 
HER2 and EGF receptors 
Since NK-1R is the high-affinity receptor for SP, we next decided to investigate its 
contribution to SP-mediated HER2 transactivation. The MDA-MB-231 cell line was transfected with 
the pcDNA3.1(+)-TACR1 vector, enriched with NK-1R+ cells by fluorescence-activated cell sorting 
(Supplementary Fig. S7A), and the expression of NK-1R confirmed by qPCR (Supplementary Fig. 
S7B). Upon SP stimulation, the levels of pHER2 Y1248 and p-p42/44-MAPK were significantly 
increased in the cells transfected with pcDNA3.1(+)-TACR1 compared to mock cells (Fig. 4A and 
Supplementary Fig. S7C), indicating that NK-1R is involved in SP-induced HER2 transactivation. 
The inhibition of TACR1 by siRNA in the SK-BR-3 and BT-474 cell lines caused a significant 
decrease in the basal levels of pHER2 (Fig. 4B). Consistent with this finding, the inhibition of NK-
1R activity by the chemical inhibitor L-733,060 for 24 hours markedly reduced pHER2 Y1248 in the 
SK-BR-3, BT-474 and MDA-MB-453 cells and pEGFR Y1068 in the MDA-MB-468 cell line (Fig. 
4C). This suggests that tumor cell oncogene addiction to NK-1R could rely in part on NK-1R-
mediated effects on HER2 and EGFR basal activity. We also observed that signal transduction 
through phospho-p42/44-MAPK in BT-474 and/or phospho-Akt in SK-BR-3, BT-474, and MDA-
MB-468 was also inhibited in cells treated with L-733,060 (Fig. 4C). Moreover, the blockade of NK-
1R, NK-2R and NK-3R in the SKBR3 cell line caused almost a complete inhibition of HER2 
phosphorylation and a significant decrease in the Akt survival signaling pathway (Fig. 4D); thereby 
further confirming the tachykinergic system to be a modulator of the steady state (or basal activation) 
of HER2. 
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Besides the well-known role of several GPCR ligands as activators of EGFR and HER2 (7, 9, 
32), their contribution to the basal activity of RTKs has not been intensely studied. For this reason, 
we next determined whether GPCR-mediated signaling modulates the activity of HER2 in BC cells. 
We observed that the inhibition of pertussis toxin-sensitive G-proteins strongly decreased the pHER2 
Y1248 in all the cell lines, and total HER2 in the SK-BR-3 and BT474 cells. In some cases a 
decrease in p42/44-MAPK and Akt were also observed (Fig. 4E and Supplementary Fig. S7D). All 
together these data suggests that G-protein signaling in BC cells directly modulates HER2 activation. 
 
Chronic overexposure to SP in vivo has mitogenic activity and enhances HER2 activation 
To further study the effects of overexposure to SP on tumor growth in vivo, we 
subcutaneously implanted mini osmotic pumps challenged to continuously deliver 500 nM of SP for 
28 days in SCID mice wearing MDA-MB-231 (HER2-) or MDA-MB-453-derived (HER2+) 
xenograft tumors. We aimed to determine whether long-term SP exposure, simulating a scenario of 
chronic inflammation, could favor the outgrowth of tumor cells with different properties and thus 
influence the progression of tumors with different phenotype: HER2- or HER2+.  
Chronic SP delivery for 28 days did not affect the tumor growth or the final tumor weight in 
any of the tumor models (Fig. 5A and B). However, we observed a significant increase of total HER2 
in the SP treated tumors by Western blot in both models (Fig. 5C) and by immunohistochemistry 
(Fig. 5D) in the MDA-MB-453. In the MDA-MB-231-derived xenografts we also detected a weak 
expression of HER2 in the treated tumors, compared with the control tumors that were totally 
negative. The MAPK pathway was also highly expressed in the MDA-MB-231 SP-treated tumors. In 
addition, in both tumor models there was a significant increase in the number of mitotic bodies 
(Supplementary Fig. S8A and B) probably due to the known mitogenic activity of SP (33, 34). These 
data suggests that the continuous presence of SP in a tumor, like in a situation of chronic 
inflammation, could enhance the expression of HER2 in tumor cells with different phenotypes. 
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The NK-1R antagonist L-733,060 inhibits tumor growth in vivo in HER2 and EGFR 
expressing tumors 
We next decided to study the effects of NK-1R inhibition on the in vivo growth of the BC cell 
lines MDA-MB-453 (HER2+), MDA-MB-468 (EGFR+), and MDA-MB-231 (HER2- and EGFR-). 
The tumor growth was significantly decreased only in MDA-MB-453 and MDA-MB-468-derived 
xenograft tumors treated with L-733,060 (5mg/kg three times weekly) (Fig. 5E and F), but not in the 
MDA-MB-231 tumors (Fig. 5G), suggesting that the anti-tumor effects of NK-1R inhibition in vivo 
depend on the modulatory properties of NK-1R signaling on HER2 and EGFR activity. Final tumor 
weight was significantly reduced by L-733,060 only in the HER2+ model derived from MDA-MB-
453, and slightly decreased in the MDA-MB-468 cells (Fig. 5H and I). On the other hand, we did not 
observe significant effect on the growth or final tumor weight of the MDA-MB-231-derived tumors 
(Fig. 5G and J). At the protein level, there were no significant differences in HER2 or EGFR, 
suggesting that NK-1R inhibition does not selects for particular cell subpopulations; and the 
treatment with L-733,060 only decreased p42/44-MAPK and Akt in the MDA-MB-231-derived 
tumors (Fig. 5K-M). In addition, we noticed a slight decrease in the expression of the COX2 pro-
inflammatory mediator as a consequence of NK-1R inhibition in all the tumor models, and a 
significant decrease in alpha-SMA (smooth muscle actin) positive cells, suggesting that the blockade 
of NK-1R modulates both tumor and stromal properties (Supplementary Fig. S9A-C). 
 
Chronic SP treatment alters cellular responses to therapies targeting HER2 and EGFR 
Since the hyperactivation of ERBB signaling by proinflammatory components may influence 
cellular responses to targeted therapies, we next studied the effects of short or chronic exposure to SP 
on the cellular responses to HER2 and EGFR inhibitors in the MDA-MB-453 (HER2+) or MDA-
MB-468 (EGFR+) cell lines. To develop a model of SP overexposure, we kept the different cell lines 
growing in the absence (control group) or presence of SP (100 nM daily) for over 5 months. The cell 
lines chronically treated with SP showed increased levels of total and activated HER2 and EGFR, 
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and in some cases a higher activation of the p42/44-MAPK and Akt pathways (Supplementary Fig. 
S10A-D).  
Next, we studied the changes in IC50 values (inhibitory concentration 50%) for the EGFR 
tyrosine kinase inhibitor AG1478, the HER2 tyrosine kinase inhibitor AG825, and the dual 
EGFR/HER2 tyrosine kinase inhibitor Lapatinib upon acute (72 hours) or chronic (5 months) SP 
treatment. A short exposure to 100 nM or 500 nM of SP had little or no effect on the IC50 value in 
any cell line, while only the response of the MDA-MB-453 cells to AG825 upon addition of 100 nM 
SP and that of the MDA-MB-468 cells to AG1478 upon 500 nM SP stimulation were significantly 
affected (Fig. 6A and B and Supplementary Table S5). However, chronic treatment with SP for up to 
5 months induced a significant increase in the viability of the MDA-MB-453 and MDA-MB-468 cell 
lines after being treated with AG1478, AG825 and Lapatinib (Fig. 6A and B and Supplementary 
Table S5), as reflected by the differences in the IC50 values. These results indicate that chronic 
exposure to SP affects the response to EGFR and HER2-targeted therapies. 
 
Combination of the NK-1R antagonist L-733,060 with anti-HER2 therapies synergistically 
inhibits the proliferation of BC cells 
We next used MTT assays and applied combination index (CI) equations (35) to determine if 
the inhibition of NK-1R activity could enhance the effects of EGFR or HER2 inhibitors. Treatment 
with L-733,060 synergized with the cytotoxic effects of AG825 (CI= 0.5686) and Lapatinib (CI= 
0.653) in the MDA-MB-453 cell line and also with Lapatinib in the MDA-MB-468 cells (CI= 
0.4494), although the combination of L-733,060 with AG1478 (CI= 1.7642) in the MDA-MB-468 
cell line indicated an antagonist effect at the doses used (Fig. 6C and Supplementary Table S5). 
These results strongly support the idea that the modulatory properties of NK-1R on ERBB receptors 
could be exploited to increase the effectiveness of targeted therapies for the treatment of BC by 
concomitant inhibition of NK-1R and ERBB receptors. 
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DISCUSSION 
Although the oncogenic addiction to HER2 signaling is therapeutically exploited for BC 
treatment, the disappointing clinical responses observed in a significant percentage of patients 
suggests that additional mechanisms regulating the HER2 pathway may be used to fine tune the 
cancer cell responses to anti-HER2 therapies. The work presented here highlights a previously 
unidentified role of SP/NK-1R autocrine/paracrine constitutive signaling as a modulator of the basal 
activation of HER2 and EGFR in BC; a mechanism with several clinical implications.  
The transmodulation of RTKs by SP and other neuropeptides and proinflammatory mediators 
(36, 37) can serve as a mechanism for RTK activation in a ligand-independent way (7). The fact that 
the steady states of HER2 and EGFR depend upon the activity of additional signaling pathways 
implies that these instigator pathways could be therapeutically used to down-regulate the activation 
of RTKs. For example, our laboratory has previously shown that SP inhibition decreases EGFR and 
HER2 activity and induces apoptosis, and that SP blockade is effective in inducing cell death even in 
cell lines that are resistant to the EGFR/HER2 inhibitors Lapatinib and Trastuzumab (17). Likewise, 
in this work we have shown that the chemical inhibition of NK-1R, alone or in combination with the 
inhibition of NK-2R and NK-3R, or the silencing of TACR1 gene by siRNA strongly decreases 
HER2 activity in all the cell lines studied, as well as the NK-1R antagonist L-733,060 reduces tumor 
growth in SCID mice harboring HER2+ or EGFR+ tumor cells. Although we did not reach high 
levels of TACR1 inhibition to avoid the effects of massive cell death, even TACR1 gene silencing by 
50%-70% showed effects on the steady state of HER2, and given the diversity of GPCRs expression 
in cancer cells, it is probable that this finding may be applied to a huge variety of ligands. It should 
be noted that a vast number of receptors involved in tumor progression, such as some cytokine and 
chemokine receptors, fall into the category of GPCRs, implying that steady G-protein activation is 
always present in cancer cells. In this context, we observed that the inhibition of G-protein-mediated 
signaling decreases HER2 activity and expression, supporting the idea that the dual blockade of 
activation and transactivation pathways could enhance the therapeutic response to particular targeted 
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therapies. Our results also imply that the lack of target dependency in some anti-HER2 therapies 
could be due in part to NK-1R transactivation mechanisms in those tumors that express the NK-1R 
receptor. In fact, we observed that an overexposure to SP in vivo increases HER2 expression in 
HER2+ or HER2- xenograft tumors, and that this could be a relevant finding to consider in relation 
to those tumors initially classified as HER2 negative; the constant signaling of SP in tumor cells 
could favor a long-term selection of cells with increase levels of HER2. Although in our model we 
did not observe an increase in tumor volume despite HER2 increase, it is likely that in a longer 
period of time this constant activation of HER2 would translate in increased tumor volume, as it can 
be expected from situations of chronic inflammation in humans. Furthermore, in vitro experiments 
demonstrate that chronic exposure to SP also increases HER2 and/or EGFR expression and 
activation in the cell lines studied. Moreover, NK-1R inhibition synergizes with anti-EGFR and anti-
HER2 therapies thereby significantly reducing cell survival. 
The modulation of RTK activation by NK-1R also suggests oncogenic co-operation between 
these two types of receptors during tumor progression. As we observed in human primary tumors, 
NK-1R and SP are highly expressed in those of the HER2+ subtype, and SP can activate HER2 in 
primary cultures derived from human tumors with and without HER2 overexpression. In addition to 
HER2 overexpression, our current results identify NK-1R and SP as two new markers associated 
with other clinicopathologic characteristics related to a poor prognosis such as p53 overexpression, 
ER negativity expression, high proliferation, and a high histological grade (38, 39).  
In addition, the relevance of SP signaling in BC could be context dependent. For instance, the 
specificity of NK-1R signal transduction depends on the formation of scaffolding protein complexes 
after its activation (40). In fact, the co-expression of EGFR and/or HER2 in the same cancer cell 
could provide SP with additional signal transduction adaptors, thus diversifying its effects. In a 
similar way, the apoptotic effects of NK-1R inhibition could depend on its ability to block the 
oncogenic dependence on HER2 and EGFR, as we observed in vivo where only HER2+ or EGFR+ 
tumors were affected after NK-1R inhibition. Moreover, as we showed in this work, not all SP 
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receptors are related to the activation of the same tumor promoting mechanism; for example NK-2R 
receptor showed a correlation with ER and PR positive tumors in contrast to NK-1R, which is 
associated with ER and PR negative tumors. Finally, SP activation of the MAPK pathway has been 
shown to be RTK dependent (40) or independent (41), suggesting a cell-type specific modulation of 
SP signaling. 
In conclusion, the results presented here imply another mechanism by which inflammation, 
via SP, could enhance tumor aggressiveness. Furthermore, the interplay between multiple signaling 
pathways, such as those controlled by the receptors NK-1R and HER2, implies that to achieve a 
complete therapeutic response with therapies designed to target RTK, both mechanisms (activation 
and transactivation) may be inhibited, as we shown for NK-1R and HER2 in the present work. 
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FOOTNOTES 
Supplementary data for this article are available at Cancer Research Online 
(http://cancerres.aacrjournals.org/).  
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FIGURE LEGENDS 
Figure 1. Expression of NK-1R, NK-2R and SP and systemic levels of SP. Representative 
immunohistochemistry images for the expression of (A) NK-1R, (B) NK-2R and (C) SP proteins in 
tumors of different subtypes. Scale bar represents 50 microns. D-F, Bar plots showing the percentage 
of cases with negative, low, medium and high expression (expression score 0 to 3, respectively) of 
NK-1R, NK-2R and SP. G-I, Box plots showing the distribution of the expression of each marker 
evaluated as a continuous variable. Significant differences by ANOVA are indicated as * P<0.05, ** 
P<0.01 and *** P<0.001. J, Serum SP levels.  Significant differences by Wilcoxon two sample test 
are indicated as * P<0.05. The boxes show the 25th to 75th percentile, and the whiskers extend to the 
5th and 95th percentiles. The yellow diamonds indicate the mean. LumA, luminal A; LumB, luminal 
B; Un, undetermined. 
 
Figure 2. Transmodulation of HER2 and EGFR by SP in human BC cell lines. A, Heatmap 
depicting the relative qPCR expression levels for EGFR, ERBB2, ERBB3 and ERBB4 genes and for 
(B) the TAC1, TACR1, TACR2 and TACR3 genes in different BC cell lines. The expression levels are 
represented as normalized values of 2-ΔΔCt. C, Immunofluorescence showing the expression of SP and 
NK-1R in different BC cell lines. Scale bar represents 50 microns. D, Representative images of 
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Western blots showing the phosphorylation (denoted by p- throughout the manuscript) of HER2 
(Y1248), EGFR (Y1048 and Y845), p42/44-MAPK and Akt at 0, 1, 2, 4, 6, 8, 10, 15 and 30 minutes 
after SP 100 nM stimulation in different BC cell lines. Tubulin was used to ensure the equal protein 
loading. The quantification of the blots is shown in Supplementary Fig. S2. 
 
Figure 3. SP-mediated transactivation of HER2 in primary cultures derived from human BC 
samples. A, Schematic outline of the experimental design used to study the effects of SP on HER2 
activation in short-term BC primary cultures. B, Estimated least squares means (LSM) of basal 
phosphorylated HER2 Y1248 fluorescence intensity in tumor subtypes (control point). C, 
Representative immunofluorescence images showing the expression of pHER2 Y1248 and pan-
cytokeratin antigens in human BC cells treated with SP. Scale bar represents 20 microns. D, 
Quantification of the immunofluorescence signal for pHER2 Y1248; values are expressed as 
estimated LSM of phosphorylated HER2. The effects of SP on each subgroup are shown as control 
(white dot), SP 6 minutes (light green dot) and SP 10 minutes (dark green dot) for each sample. 
Statistical differences of LSM are indicated as * P<0.05, ** P<0.01 and *** P<0.001. Error bars 
represent 95% confidence interval.  
 
Figure 4. NK-1R signaling modulates EGFR and HER2 activity in BC cells. Representative 
images of Western blots corresponding to experiments showing: A, the contribution of NK-1R to the 
phosphorylation of HER2 and p42/44-MAPK in the MDA-MB-231 cell line transfected with 
pcDNA3.1(+)-TACR1 or the empty vector and treated with SP 100 nM; B, the effects of TACR1 
inhibition by siRNA on the steady state of pHER2 in different BC cell lines. NK-1R expression is 
shown as a control for siRNA efficiency; C, the effects of L-733,060 20 μM (SKBR3), 20 μM (BT-
474), 30 μM (MDA-MB-453)) on the phosphorylated and total levels of HER2, EGFR, p42/44-
MAPK and Akt in different BC cell lines; D, the effects of the triple inhibition of NK-1R, NK-2R 
and NK-3R with L-733,060 (20 μM), MEN 10376 (30 μM) and SB 218795 (20 μM) respectively, on 
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the phosphorylation of HER2, p42/44-MAPK and Akt in the SKBR3 cell line; E, the effects of the 
G-protein inhibitor pertussis toxin (PTX) on the phosphorylated and total levels of HER2, p42/44-
MAPK and Akt in different BC cell lines. The plots accompanying each panel show the 
densitometric quantification of the Western blots relative to the expression of tubulin, which was 
used to ensure equal protein loading. All the Western blots and the quantitative data are for a 
minimum of 3 replicates and are presented as mean + S.D. and compared by t-test (two-tailed) as * 
P<0.05, ** P<0.01 and *** P<0.001. 
 
Figure 5. Modulation of tumor growth in vivo by SP/NK-1R. A, Volume of MDA-MB-231 and 
MDA-MB-453 xenograft tumors treated with saline or SP for 27 days (mean ± s.e.m); B, final tumor 
weight. Sample size (n) is indicated. C, Western blot of MDA-MB-231 and MDA-MB-453 
xenografts, and box plots showing the densitometric quantification (right panels, tubulin was used to 
ensure equal protein loading) for the proteins indicated. D, Representative images for the 
immunohistochemical detection of HER2. Scale bar represents 50 microns. Volume of (E) MDA-
MB-453, (F) MDA-MB-468 and (G) MDA-MB-231 xenograft tumors treated with the NK-1R 
inhibitor L-733,060 (mean ± s.e.m) and (H, I, J) final tumor weight, respectively. Western blot of (K) 
MDA-MB-453, (L) MDA-MB-468, and (M) MDA-MB-231 xenografts and box plots showing the 
densitometric quantification (right panel, tubulin was used to ensure equal protein loading) for the 
proteins indicated. The boxes show the 25th to 75th percentile, and the whiskers extend to the 5th 
and 95th percentiles. Yellow diamonds in each plot indicate the mean. Data was compared by t-test 
(two-tailed). Significant P values are indicated as * P<0.05, and ** P<0.01. 
 
Figure 6. The NK1 antagonist L-733,060 synergizes with anti-HER2 therapies. MTT assays 
comparing IC50 for the drugs indicated. Colored circles represent IC50 ± 95% confidence interval 
for each treatment in (A) MDA-MB-453 and (B) MDA-MB-468 upon short (72 hours) or chronic (5 
months) SP exposure. Curve fitting and statistical analysis was performed by F test (extra sum of 
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squares). Significant P values are indicated as * P<0.05, ** P<0.01 and *** P<0.001. C, 
Combination assay comparing the effect of NK-1R antagonist L-733,060 with the combination of 
AG825, AG1478 and Lapatinib. Diamonds represent CI of drug interactions. 
 
 
 






